Efficacy and Safety of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion Administered as Monotherapy in Patients with Parkinson's Disease

被引：0
|
作者：
Aldred, J.
Henriksen, T.
Bouchard, M.
Martinez-Castrillo, J.
Soileau, M.
Spiegel, A.
Bergmann, L.
Gupta, R.
Kukreja, P.
Standaert, D.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
19
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF FOSLEVODOPA/FOSCARBIDOPA CONTINUOUS SUBCUTANEOUS INFUSION ADMINISTERED AS MONOTHERAPY IN PATIENTS WITH PARKINSON'S DISEASE
    Aldred, J.
    Henriksen, T.
    Bouchard, M.
    Martinez-Castrillo, J. C.
    Soileau, M. J.
    Spiegel, A.
    Bergmann, L.
    Gupta, R.
    Kukreja, P.
    Standaert, D. G.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [2] Vyalev - Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2025, 67 (1719):
  • [3] Effects of continuous subcutaneous infusion of foslevodopa/foscarbidopa on quality-of-life in Parkinson's patients
    Gandor, F.
    Bouchard, M.
    Bergmans, B.
    Pahwa, R.
    Isaacson, S.
    Spiegel, A.
    Bergmann, L.
    Jia, J.
    Shah, M.
    Antonini, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 304 - 304
  • [4] Effects of continuous subcutaneous infusion of foslevodopa/foscarbidopa on quality-of-life in Parkinson's patients
    Gandor, F.
    Bouchard, M.
    Bergmans, B.
    Pahwa, R.
    Isaacson, S.
    Spiegel, A.
    Bergmann, L.
    Jia, J.
    Shah, M.
    Waern, J.
    Antonini, A.
    AUSTRALASIAN JOURNAL ON AGEING, 2024, 43 : 32 - 32
  • [5] EFFECTS OF CONTINUOUS SUBCUTANEOUS INFUSION OF FOSLEVODOPA/FOSCARBIDOPA ON SLEEP DYSFUNCTION IN PEOPLE WITH PARKINSON'S
    Hauser, R.
    Bergmans, B.
    Malaty, I.
    Cobb, D.
    Homola, J.
    Bergmann, L.
    Gupta, R.
    Jia, J.
    Shah, M.
    Chaudhuri, K. R.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [6] Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease
    Rosebraugh, Matthew
    Voight, Eric A.
    Moussa, Ehab M.
    Jameel, Feroz
    Lou, Xiaochun
    Zhang, Geoff G. Z.
    Mayer, Peter T.
    Stolarik, Deanne
    Carr, Robert A.
    Enright, Brian P.
    Liu, Wei
    Facheris, Maurizio F.
    Kym, Philip R.
    ANNALS OF NEUROLOGY, 2021, 90 (01) : 52 - 61
  • [7] Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank Compared to Abdomen in Parkinson's Disease Patients
    Han, Y.
    Kalluri, H.
    Jeong, A.
    Locke, C.
    Facheris, M.
    Gupta, S.
    Rosebraugh, M.
    MOVEMENT DISORDERS, 2023, 38 : S27 - S27
  • [8] Efficacy and safety of foslevodopa/foscarbidopa subcutaneous infusion in patients with prior deep brain stimulation
    Henriksen, T.
    Martinez-Castrillo, J.
    Huisman, M.
    Dhanani, S.
    Peckham, E.
    Aldred, J.
    Bergmann, L.
    Shah, M.
    Gupta, R.
    Kukreja, P.
    Fung, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 169 - 170
  • [9] EFFICACY AND SAFETY OF FOSLEVODOPA/FOSCARBIDOPA SUBCUTANEOUS INFUSION IN PATIENTS WITH PRIOR DEEP BRAIN STIMULATION
    Henriksen, T.
    Martinez-Castrillo, J. C.
    Huisman, M.
    Dhanani, S.
    Peckham, E.
    Aldred, J.
    Bergmann, L.
    Shah, M.
    Gupta, R.
    Kukreja, P.
    Fung, V. S.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [10] Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance
    Fung, Victor S. C.
    Aldred, Jason
    Arroyo, Martha P.
    Bergquist, Filip
    Boon, Agnita J. W.
    Bouchard, Manon
    Bray, Sarah
    Dhanani, Sara
    Facheris, Maurizio F.
    Fisseha, Nahome
    Freire-Alvarez, Eric
    Hauser, Robert A.
    Jeong, Anna
    Jia, Jia
    Kukreja, Pavnit
    Soileau, Michael J.
    Spiegel, Amy M.
    Talapala, Saritha
    Tarakad, Arjun
    Urrea-Mendoza, Enrique
    Zamudio, Jorge
    Pahwa, Rajesh
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2024, 10
12345